High dose oral fluconazole for oropharyngeal candidosis in AIDS

1990 ◽  
Vol 25 (4) ◽  
pp. 720-721 ◽  
Author(s):  
A. M. ANSARI ◽  
I. M. GOULD ◽  
J. G. DOUGLAS
Keyword(s):  
High Dose ◽  
Oral Fluconazole ◽  
Dose Oral

scholarly journals High-Dose Oral Fluconazole Therapy Effective for Cutaneous Leishmaniasis Due to Leishmania (Vianna) braziliensis

2011 ◽  
Vol 53 (7) ◽  
pp. 693-695 ◽  
Author(s):  
A. Q. Sousa ◽  
M. S. Frutuoso ◽  
E. A. Moraes ◽  
R. D. Pearson ◽  
M. M. L. Pompeu
Keyword(s):  
Cutaneous Leishmaniasis ◽  
High Dose ◽  
Oral Fluconazole ◽  
Dose Oral ◽  
Fluconazole Therapy

Successful treatment of disseminated cryptococcosis with high-dose oral fluconazole

AIDS ◽  
1993 ◽  
Vol 7 (12) ◽  
pp. 1685-1687 ◽  
Author(s):  
O Sitbon ◽  
T Fourme ◽  
P Bourée ◽  
L Du Pasquier ◽  
S Salmeron
Keyword(s):  
Successful Treatment ◽  
High Dose ◽  
Oral Fluconazole ◽  
Dose Oral

scholarly journals Associations between low- and high-dose oral fluconazole and pregnancy outcomes: 3 nested case–control studies

2019 ◽  
Vol 191 (7) ◽  
pp. E179-E187 ◽  
Author(s):  
Anick Bérard ◽  
Odile Sheehy ◽  
Jin-Ping Zhao ◽  
Jessica Gorgui ◽  
Sasha Bernatsky ◽  
...  
Keyword(s):  
Pregnancy Outcomes ◽  
Case Control ◽  
High Dose ◽  
Case Control Studies ◽  
Oral Fluconazole ◽  
Dose Oral ◽  
Nested Case Control

scholarly journals High-dose oral and intravenous rifampicin for the treatment of tuberculous meningitis in predominantly HIV-positive Ugandan adults: a phase II open-label randomised controlled trial

2021 ◽  
Author(s):  
Fiona V Cresswell ◽  
David B Meya ◽  
Enock Kagimu ◽  
Daniel Grint ◽  
Lindsey te Brake ◽  
...  
Keyword(s):  
Adverse Events ◽  
Phase Ii ◽  
Tuberculous Meningitis ◽  
Geometric Mean ◽  
Standard Of Care ◽  
Hiv Positive ◽  
High Dose ◽  
Open Label ◽  
Dose Oral ◽  
Csf Levels

Abstract Background High-dose rifampicin may improve outcomes of tuberculous meningitis (TBM). Little safety or pharmacokinetic (PK) data exist on high-dose rifampicin in HIV co-infection, and no cerebrospinal fluid (CSF) PK data exist from Africa. We hypothesized that high-dose rifampicin would increase serum and CSF concentrations without excess toxicity. Methods In this phase II open-label trial, Ugandan adults with suspected TBM were randomised to standard-of-care control (PO-10, rifampicin 10mg/kg/day), intravenous rifampicin (IV-20, 20mg/kg/day), or high-dose oral rifampicin (PO-35, 35mg/kg/day). We performed PK sampling on day 2 and 14. The primary outcomes were total exposure (AUC0-24), maximum concentration (Cmax), CSF concentration and grade 3-5 adverse events. Results We enrolled 61 adults, 92% were HIV-positive, median CD4 count was 50cells/µL (IQR 46–56). On day 2, geometric mean plasma AUC0-24hr was 42.9h.mg/L with standard-of-care 10mg/kg dosing, 249h.mg/L for IV-20 and 327h.mg/L for PO-35 (P<0.001). In CSF, standard-of-care achieved undetectable rifampicin concentration in 56% of participants and geometric mean AUC0-24hr 0.27mg/L, compared with 1.74mg/L (95%CI 1.2–2.5) for IV-20 and 2.17mg/L (1.6–2.9) for PO-35 regimens (p<0.001). Achieving CSF concentrations above rifampicin minimal inhibitory concentration (MIC) occurred in 11% (2/18) of standard-of-care, 93% (14/15) of IV-20, and 95% (18/19) of PO-35 participants. Higher serum and CSF levels were sustained at day 14. Adverse events did not differ by dose (p=0.34) Conclusion Current international guidelines result in sub-therapeutic CSF rifampicin concentration for 89% of Ugandan TBM patients. High-dose intravenous and oral rifampicin were safe, and respectively resulted in exposures ~6- and ~8-fold higher than standard-of-care, and CSF levels above the MIC

High-Dose Oral and Intravenous Metoclopramide in Doxorubicin/Cyclophosphamide-Induced Emesis A Randomized Double-Blind Study

1987 ◽  
Vol 10 (3) ◽  
pp. 257-263 ◽  
Author(s):  
Stephen B. Edge ◽  
William K. Funkhouser ◽  
Arlene Berman ◽  
Claudia Seipp ◽  
Anne Tanner ◽  
...  
Keyword(s):  
Blind Study ◽  
High Dose ◽  
Double Blind Study ◽  
Double Blind ◽  
Dose Oral
Sign in / Sign up

Export Citation Format

Share Document